License Agreement Dated May 31, 2000



 Exhibit 10.1 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  
 LICENSE AGREEMENT 
  
 THIS LICENSE AGREEMENT is made as of the 31st day of May, 2000 by and between
BENTLEY PHARMACEUTICALS, INC., a Delaware corporation, with offices at 65 Lafayette Road, 3rd Floor, North Hampton, New Hampshire 03862-2403 (hereinafter, “BENTLEY” or “Licensor”), and AUXILIUM A2, INC., a Delaware corporation
having a principal place of business at 160 W. Germantown Pike, Suite D-5, East Norriton, Pennsylvania 19401 (hereinafter, “AUXILIUM” or” Licensee”). BENTLEY and AUXILIUM may be referred to as a “Party” or,
collectively, as “Parties.” 
  
 RECITALS 
  
 WHEREAS AUXILIUM is engaged in the research, development, manufacture, marketing and sale of
pharmaceutical products; 
  
 WHEREAS BENTLEY is engaged in the development of
pharmaceutical formulations and drug delivery systems and has developed certain formulations which contain a therapeutic drug and drug delivery systems included under BENTLEY Patents and BENTLEY Technology; 
  
 WHEREAS under a Research Services Agreement of even date herewith (the “Research
Agreement”) BENTLEY will prepare and test topical pharmaceutical formulations, excluding patch applications, which contain the therapeutic drug testosterone and CPE-215 (hereinafter, the “Compound”) under BENTLEY Patents and BENTLEY
Technology; 
  
 WHEREAS AUXILIUM wishes to obtain a license under BENTLEY Patents
and BENTLEY Technology to undertake development of products containing the Compound which meet criteria set forth in the Research Agreement for commercialization in the Territory; and 
  
 WHEREAS BENTLEY is willing to grant such a license under certain terms and conditions. 
  
 NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, and
INTENDING TO BE LEGALLY BOUND HEREBY, the Parties agree as follows: 
  
 ARTICLE I 
 DEFINITIONS 
  
 1.1 The following terms, as used herein, shall have the following meanings: 
  
 “Act” shall mean the United States Federal Food Drug and Cosmetic Act and applicable regulations. 
  
 “Affiliate” means, when used with reference to a Party, any person
directly or indirectly Controlling, Controlled by or under common Control with a Party. 
  
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  









 “Bankruptcy Event” means the person in question becomes insolvent, or voluntary or involuntary
proceedings by or against such person are instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for such person, or proceedings are instituted by or against such person for corporate reorganization or the
dissolution of such person, which proceedings, if involuntary, shall not have been dismissed within one hundred eighty days after the date or filing, or such person makes an assignment for the benefit of creditors, or substantially all of the assets
of such person are seized or attached and not released within one hundred eighty days thereafter. 
  
 “BENTLEY Know-How” shall mean any and all present and future information and any materials, including, without limitation, formulations,
processes, techniques, formulas, biological, chemical, assay control and manufacturing data, methods, software, equipment designs, know-how, and trade secrets, patentable or otherwise, tangible or intangible, that are owned or controlled by Licensor
that relate to the preparation, purification, characterization, stabilization, processing, and formulation and/or use of a testosterone topical formulation containing CPE-215. 
  
 “BENTLEY Patents” shall mean United States Patent No. 5,023,252 and any and all continuations,
continuations-in-part, additions, divisions, renewals, extensions, re-examinations and reissues thereof and any and all foreign counterparts of the foregoing as set forth in Schedule A hereto and any other Bentley U.S. or foreign patent application
which is filed hereafter and which includes a claim that covers a testosterone topical formulation which contains CPE-215 and/or the preparation and/or use thereof and any U.S. or foreign patent issuing therefrom and any renewal, extension,
re-examination or reissue thereof. 
  
 “BENTLEY
Technology” means BENTLEY Know-How and Improvements. 
  
 “Calendar Quarter” means each three-month period, or any portion thereof, beginning on January 1, April 1, July 1 and October 1. 
  
 “Combination Products” means any and all pharmaceutical compositions which contain: (A) testosterone as an active ingredient in combination with
any other steroids, hormones, somatotropics, emollients, or therapeutic soy products; and (B) the Compound; and which fall within the scope of any composition, method, or article claim of the BENTLEY Patents and which is intended to be applied
topically to the user of the composition. 
  
 “Compound”
is defined above in the Recitals. 
  
 “Confidential
Information” means (i) BENTLEY Technology, (ii) any other information or material in tangible form that is confidential or proprietary to the furnishing Party at the time it is delivered to the receiving Party, (iii) proprietary information of
the furnishing party, (iv) information that is furnished orally if the furnishing party identifies such information as confidential or proprietary when it is disclosed, and (v) patent applications not yet in the public domain. 
  

 2 








 “Control”, “Controlling,” and “Controlled by” mean the direct or indirect
ownership of over 50% of the outstanding voting securities of an entity, or the right to receive over 50% of the profits or earnings of a person, or the right to control the policy decisions of a person. 
  
 “Effective Date” means the date of receipt by BENTLEY of written
notice from AUXILIUM pursuant to Section 9.1 of the Research Agreement that it wishes to proceed with development of Product. Such notice shall be provided on or before 30 September, 2000. 
  
 “Improvement” shall mean any formulations and/or any enhancement or
other desirable change to the technical/pharmacological characteristics of formulations of Product, whether patentable or not, which is useful for commercializing Product developed by BENTLEY during the term of this Agreement which may take the form
of, without limitation, new or improved methods of administration, manufacture, improved shelf life or packaging. 
  
 “IND” shall mean an Investigational New Drug Exemption application filed under the Act, or comparable filing in any major market in the
Territory the approval of which permits clinical investigation of Product in humans. 
  
 “NDA” means a New Drug Application submitted under the Act to permit commercial sale of Product in the United States or a comparable marketing license in another major market in the Territory. 
  
 “Net Sales Price” means the gross amount charged by Licensee for
the sale of a Product, net of returns and credits for rejected goods, and after deducting (i) trade and quantity discounts actually allowed, (ii) sales, use or value added taxes, the legal obligation of which is on Licensee, and (iii) freight
allowances, insurance and customs duties, to the extent any of the foregoing are identified on the invoice for the product. If a product is sold for consideration other than solely cash, the fair market value of such other consideration shall be
included in the Net Sales Price. If a Product is sold in a package or kit containing another product which is not a Product, the Net Sales price for purposes of calculating the royalty under Section 3.2 hereof shall be calculated by multiplying the
Net Sales Price of the combination product by the fraction of A/A+B, where “A” is the Net Sales Price of Product when sold separately “B” is the Net Sales Price of the other product or products when sold separately. If either the
Product or the other product is not sold separately, the Net Sales Price of the Product shall be negotiated in good faith by the Parties. 
  
 “Person” or “Persons” means any corporation, partnership, joint venture or natural person. 
  
 “Products” means any and all pharmaceutical compositions which
contain (A) testosterone as the single active drug ingredient; and (B) the Compound; and which fall within the scope of any composition, method or article claim of the BENTLEY Patents and which is intended to be applied topically to the user of the
composition. 
  
 “Sale” or any variation thereof means
the sale, assignment, lease or other disposition of a Product by Licensee to a non-Affiliate. A Product shall be deemed to have been sold for purposes of calculating royalties under Article III hereof upon the first to occur of the following: (i)
the transfer of title in the Product from Licensee to a non-Affiliate; or (ii) shipment of the Product from the manufacturing facilities of Licensee to a non-Affiliate. 
  

 3 








 “Territory” shall mean all countries and territories of the world except Spain. 
  
 “Use Patents” shall mean any patent granted in the Territory for
the use of the Product in a specific therapeutic indication. 
  
 ARTICLE II 
 GRANT OF LICENSE 
  
 2.1 Grant of License. Subject to the terms and conditions contained in this Agreement, the Licensor hereby grants to Licensee a sole and exclusive,
worldwide (except Spain), royalty-bearing license under BENTLEY Patents and BENTLEY Technology with the right to sublicense to make, have made, use and sell Products in the Territory pursuant to the terms and conditions of this License Agreement. In
addition, Licensee shall have the exclusive right to enter into another License Agreement with BENTLEY to acquire rights in BENTLEY Patents and BENTLEY Technology for the development of Combination Products, such right to expire upon the termination
of this Agreement. Licensor and Licensee agree to negotiate the terms of such License Agreement in good faith. 
  
 2.2 Disclosure of BENTLEY Know-How. Promptly following the Effective Date BENTLEY shall make available to Licensee any and all BENTLEY Know How not
disclosed under the Research Agreement to enable Licensee to develop Products. 
  
 ARTICLE III 
 PAYMENTS IN CONSIDERATION FOR LICENSE 
  
 3.1 Milestone Payments. In partial consideration for the license rights
granted hereunder, Licensee shall make the following non-refundable payments to Licensor within ten (10) days after the achievement of the following milestones in the development of the first Product: 
  
 Milestone One - On the date of execution of this Agreement: $[**].

  
 Milestone Two - On the Effective Date: $[**]. 
  
 Milestone Three - Three (3) months after first approval for commercialization
in any major market (United States, Germany, France or Japan): $[**]. 
  
 3.2 Royalties. In further consideration for the license rights granted under this Agreement Licensee shall also pay to Licensor the following royalty amounts on annual Net Sales of Products in those countries in the Territory in which

  
 (a) there is an enforceable BENTLEY Patent at
the time of sale: 
  
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN
OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  

 4 









			
	The First $[**] Million of Annual Net Sales	  	[**]%
	The Next $[**] Million of Annual Net Sales	  	[**]%
	The Next $[**] Million of Annual Net Sales	  	[**]%
	Net Sales over the First $[**] Million of Annual Net Sales	  	[**]%

  
 (b)
there is no enforceable BENTLEY Patent in the country when there is an enforceable BENTLEY Patent in another country at the time of sale: 
  

			
	All Annual Net Sales over $[**]	  	[**]%

  
 (c)
there is no enforceable BENTLEY Patent in any country at the time of sale: 
  

			
	All Annual Net Sales over $[**]	  	[**]%

  
 3.3 Royalty Payments.
Royalties under this Agreement shall be paid within ninety (90) days in the case of no sublicense, and one hundred twenty (120) days, in the case of royalties received from a sublicensee, following the last day of the Calendar Quarter in which the
royalties and other amounts accrue. The last such payment shall be made within ninety (90) days after termination of this Agreement. Payments shall be deemed paid as of the day on which they are received by Licensor in the manner designated by
Section 3.4. Licensor and Licensee agree to negotiate in good faith any future implication on royalties caused by withholding taxes. 
  
 3.4 Currency, Place of Payment, Interest. 
  
 (a) All dollar amounts referred to in this Agreement shall be expressed in United States dollars. All payments to the Licensor under this
Agreement shall be made in United States dollars, as directed by the Licensor, by wire transfer to the Licensor or in such other manner as the Licensor may designate from time to time. 
  
 (b) If Licensee receives revenues from sales of Products in a currency other than United States dollars,
royalties shall be converted into United States dollars at a quarterly conversion rate for each foreign currency calculated as the average of the conversion rate for such currency published in the Exchange Rates table in the eastern edition of the
Wall Street Journal for the first business day of each month of the quarter. 
  
 (c) Amounts that are not paid when due shall accrue interest from the due date until paid, at an annual rate equal to the Prime Rate plus 1% as published in the eastern edition of the Wall Street Journal as of the due
date. The Licensor may treat unpaid payments as a breach of this Agreement in a manner consistent with Article XI notwithstanding the payment of interest. 
  
 3.5 Records. Licensee will maintain complete and accurate books and records which enable the royalties payable hereunder to be verified. The records for
each Calendar Quarter shall be maintained for three years. Upon reasonable prior notice to Licensee, the Licensor and its accountants shall have access to the books and records of Licensee necessary to enable Licensor to verify the royalties paid
hereunder. Such access shall be available during normal business hours from 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.


  

 5 








 time to time during the term of this Agreement, and, during the period from expiration or termination of this Agreement
until three years after such date, not more often than once each calendar year. If it is ultimately determined that Licensee has underpaid royalties by 10% or more, Licensee will pay the costs and expenses of the Licensor’s accountant in
connection with its review or audit of the sales records of the Product, together with any interest as provided in Section 3.4 (c) above. 
  
 3.6 Co-Marketing. In the event Licensee enters into a co-marketing or sub-license arrangement with a third-party, the royalty payments due to Licensor
will be calculated using Net Sales of Product of Licensee and Net Sales of Product of Licensee’s co-marketing partner combined. 
  
 3.7 Sales in Spain. Licensor shall pay to Licensee a royalty of [**]% on all annual Net Sales in Spain over $[**] Million. 
  
 ARTICLE IV 
 CERTAIN OBLIGATIONS OF LICENSEE 
  
 4.1 Government Approvals. Licensee will be responsible for obtaining, at its cost and expense, all governmental approvals required for marketing and sale of Products in the Territory. 
  
 4.2 Licensee Efforts. 
  
 (a) Licensee shall use its reasonable best efforts to
develop for commercial sale and to market Products in the Territory, and to continue to market Products as long as commercially viable, all in a manner consistent with sound and reasonable business practices. For purposes of this Agreement
reasonable best efforts in the case of Product development in any major market shall mean at least that diligence required on the part of an NDA applicant in undertaking the development of a drug product to qualify for the maximum patent term
extension under the Act. 
  
 (b) Licensee shall
notify Licensor within ten (10) days after the first commercial sale of a Product and of any formal written notice from the FDA or other equivalent regulatory authority (“Regulator”) in which CPE-215 is the Regulator’s primary focus,
apart from the use of CPE-215 in the Licensee’s Product. 
  
 4.3 Manufacture of Product. Prior to commercialization of the Product, the Parties may, if appropriate for both parties, negotiate in good faith a manufacturing and supply agreement to provide for Licensor to fulfill the manufacturing
requirements of Licensee for Product for sale in the European market. The cost of such manufacturing shall not be greater than * percent (*%) of the cost of any competitor cGMP contract manufacturing facility that proposes to manufacturer the
Product for Licensee. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.


  

 6 








 ARTICLE V 
 WARRANTIES AND REPRESENTATIONS 
  
 5.1 Mutual Representations. Each of the Parties hereto represents, warrants and covenants: 
  
 (i) It is a corporation or entity duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation or formation. 
  
 (ii) The execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite corporate action.

  
 (iii) It has the power and authority to execute and deliver this Agreement and
perform its obligations hereunder. 
  
 (iv) The execution, delivery and
performance by such Party of this Agreement does not and will not conflict with or result in breach of the terms and provisions of any other agreement or constitute a default under (a) a loan agreement, guaranty, financing agreement, affecting a
product or other agreement or instrument binding or affecting it or its property; (b) the provisions of its charter or operative documents or bylaws; or (c) any order, writ, injunction or decree of any court or governmental authority entered against
it or by which any of its property is bound. 
  
 (v) The execution, delivery and
performance of this Agreement by such Party does not require the consent, approval or authorization of, or notice, declaration, filing or registration with, any governmental or regulatory authority in the Territory and the execution, delivery and
performance of this Agreement does not violate any law, rule or regulation applicable to such Party. 
  
 (vi) This Agreement has been duly authorized, executed and delivered and constitutes such Party’s legal, valid, and binding obligation enforceable against it in accordance with its terms subject, as to
enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and to the availability of particular remedies under general equity principles. 
  
 (vii) It shall comply with all applicable laws and regulations relating to its activities
under this Agreement. 
  
 (viii) Each warrants that it is not debarred and has not
and will not use in any capacity the services of any person debarred under subsections 306 (a) and (b), of the Generic Drug Enforcement Act of 1992. If at any time during the term of this Agreement this warranty is no longer accurate, the affected
party shall immediately notify the other. 
  
 5.2 BENTLEY
Warranties 
  
 (i) BENTLEY Patents. BENTLEY represents and warrants that: (a)
BENTLEY is the owner of all right, title and interest in and to the BENTLEY Technology and BENTLEY Patents; and (b) BENTLEY has not received any written notice that the Technology or Patents infringes the proprietary rights of any third-party nor is
the Licensor in any other way aware of any infringement of third-party proprietary rights; (d) except for those claims explained in detail in Schedule B hereto, 
  


 7 








 there are no claims, judgments or settlements against or owed by BENTLEY, or pending or threatened claims, or litigation,
relating to BENTLEY Patents. 
  
 ARTICLE VI 
 INSURANCE 
  
 6.1 Insurance Requirements for Licensee. Prior to commencing work with Product in human clinical trials under this Agreement and during the entire term of
this Agreement and for a period of three (3) years thereafter, AUXILIUM, at its sole expense, shall maintain in full force and effect with an insurance company or companies having an A. M. Best Rating of “A-: Class VII” or better and
supply a Certificate of Insurance to BENTLEY evidencing Product Liability insurance (including coverage for human clinical trials and contractual liability) coverage in the amount of three million dollars ($3,000,000) per each occurrence and in the
general aggregate, respectively, during the clinical trial phase and prior to commercialization of the Products and three million dollars ($3,000,000) per each occurrence and in the general aggregate, respectively. Endorsement shall be furnished
reflecting the inclusion of BENTLEY, its officers, directors and employees as additional insured. The policy providing the above insurance shall be endorsed to contain the following undertaking: “It is agreed that this insurance will not be
cancelled, materially changed or non-renewed without at least thirty (30) days notice to BENTLEY, by certified mail-Return Receipt Requested.” Any type of insurance or increase in liability limits not described in the foregoing which AUXILIUM
requires for its own protection shall be its own responsibility and at its sole expense. The minimum insurance amounts specified herein shall not be deemed a limitation on AUXILIUM’S indemnification liability under this Agreement. 

 
 6.2 Insurance Requirements for Licensor. Prior to commencing work with
Product in human clinical trials under this Agreement and during the entire term of this Agreement and for a period of three (3) years thereafter, BENTLEY, at its sole expense shall maintain in full force and effect with an insurance company or
companies having A. M. Best Rating of an “A-: Class VII” or better and supply a Certificate of Insurance to AUXILIUM evidencing Product Liability insurance (including coverage for human clinical trials and contractual liability) coverage
in the amount of three million dollars ($3,000,000) per each occurrence and in the general aggregate, respectively. The policy providing the above insurance shall be endorsed to contain the following undertaking: “It is agreed that this
insurance will not be cancelled, materially changed or non-renewed without at least thirty (30) days notice to AUXILIUM, by certified mail-”Return Receipt Requested”. Any type of insurance or increase in liability limits not described in
the foregoing which BENTLEY requires for its own protection shall be its own responsibility and at its sole expense. 
  
 ARTICLE VII 
 INDEMNIFICATION 
  
 7.1 Indemnification by BENTLEY. BENTLEY will indemnify and hold AUXILIUM, its
directors, officers, employees and agents harmless against any and all liability, damage, loss, cost or expense (including reasonable attorney’s fees) resulting from any third-party claims made or suits brought against AUXILIUM which arise from
an act or failure to act by BENTLEY or BENTLEY’s breach of its representations, warranties or agreements contained herein. 
  
 7.2 Indemnification by AUXILIUM. AUXILIUM will indemnify and hold BENTLEY, its directors, officers, employees and agents harmless against any and all
liability, damage, loss, cost or expense 
  

 8 








 (including reasonable attorney’s fees) resulting from any third-party claims made or suits brought against BENTLEY
which arise from the breach of any of AUXILIUM’s representations, warranties or agreements contained herein, or which arise out of the development, manufacture, promotion, distribution, use, testing or sale, distribution or other disposition of
Product, including, without limitation, any claims, express, implied or statutory, made as to the efficacy, safety or use to be made of Product, and claims made by reason of any Product labeling or any packaging containing Product. This
indemnification obligation shall not apply where the basis for the claim is the negligence or willful malfeasance of BENTLEY. 
  
 7.3 Limitations on Indemnification Obligations. BENTLEY AND AUXILIUM EACH AGREE THAT IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR INDIRECT,
INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM A DEFAULT OR BREACH OF THIS AGREEMENT. 
  
 7.4 Procedures. The indemnified Party shall notify the indemnifying Party of any claim or action giving rise to a liability within fifteen (l5) days after
receipt of knowledge of the claim. If notice is not given within fifteen (15) days, the indemnifying Party shall maintain its obligation to indemnify unless such failure to timely notify has a material, adverse effect on the outcome of the claim.
The indemnifying Party shall control the defense or settlement of the claim. However, the indemnifying Party shall not settle or compromise any such claim or action in a manner that imposes any restrictions or obligations on the indemnified Party
without the indemnified Party’s written consent. The indemnified Party shall cooperate reasonably, assist and give all necessary authority and reasonably required information. 
  
 ARTICLE VIII 
 INTELLECTUAL PROPERTY 
  
 8.1 Intellectual Property
Rights. The inventorship of inventions developed under this Agreement and relating to Products (“Inventions”) shall be determined in accordance with U.S. Law. Inventions made solely by employees of BENTLEY or owned by BENTLEY
(“BENTLEY Inventions”) shall be the exclusive property of BENTLEY. Inventions made solely by employees of AUXILIUM (“AUXILIUM Inventions”) shall be the exclusive property of AUXILIUM, except that AUXILIUM Inventions that relate
to the use of Products shall be the joint property of AUXILIUM and BENTLEY, each with an undivided one-half interest. Inventions other than BENTLEY Inventions and AUXILIUM Inventions shall belong jointly to BENTLEY and AUXILIUM, each with an
undivided one-half interest. 
  

 9 








 ARTICLE IX 
 PATENTS, TRADEMARKS AND INFRINGEMENT 
  
 9.1 Prosecution of Patents. 
  
 (a) The
Licensor shall be solely responsible for preparing, prosecuting and maintaining the BENTLEY Patents. 
  
 (b) Each Party shall cooperate with the other Party to execute all required papers and instruments and to make all required oaths and
declarations as may be necessary in the preparation and prosecution of all such patents and other applications and protections referred to in this Section 9.1. 
  

9.2 Ownership. The Licensor shall retain all right, title and interest in and to the BENTLEY Patents and any patents, copyrights and other protections
related thereto, regardless of which party prepares, prosecutes or maintains the patents, copyrights or other protections related to the BENTLEY Technology, subject to the express license granted to Licensee under this Agreement. 
  
 (a) In the event of Licensor wishing to abandon any BENTLEY
Patents, Licensor will offer to assign to Licensee, free of charge, any such Patent prior to effectuating the abandonment. Licensee will bear the costs connected to any assignment hereunder. In the event that any of the BENTLEY Patents is assigned
to AUXILIUM and AUXILIUM decides thereafter to abandon the assigned Patent, AUXILIUM agrees that, at the request of BENTLEY, it will offer to assign the assigned Patent to a third-party licensee that is licensed by BENTLY under the assigned Patent
as such third-party licensee is identified by BENTLEY to AUXILIUM. 
  
 9.3 Trademarks. Licensee shall have the right, in its sole discretion and at its own expense, to select and register such trademarks as it wishes to employ in connection with the sale of the Products throughout the Territory and Licensee
shall have legal and equitable ownership of the entire right, title and interest in and to the trademarks and registrations Licensee elects to use. Licensee will acknowledge BENTLEY’S CPE-215 by adding “CPE-215(TM), BENTLEY” to its
listing of ingredients wherever such listing is appropriate or used by Licensee. It is hereby expressly agreed that this Section 9.3 shall survive the expiration or termination of this Agreement. 
  
 9.4 Infringement of Patents. If either Party has knowledge of any
infringement of BENTLEY Patents or BENTLEY Technology, the Party having such knowledge shall promptly inform the other of such infringement. The Parties shall thereafter discuss what action should be taken, including whether any legal proceeding
should be instituted. If the Parties mutually agree on the course of action to be taken in respect of any such infringement, they shall jointly select counsel and equally share any expenses. Any settlement or recovery shall be shared equally by the
Parties. If either party determines to take action, but the other Party does not desire to do so, the first Party may take action at its own expense and through counsel of its own choice, and any settlement or recovery shall in such case belong
solely to the Party taking action. 
  
 9.5 If one party institutes
and carries on a legal proceeding to enforce a BENTLEY Patent against an alleged infringing party, the other Party shall fully cooperate with and supply all assistance reasonably requested by the Party instituting and carrying or such proceeding.

  

 10 








 ARTICLE X 
 CONFIDENTIALITY 
  
 10.1
Confidentiality 
  
 (a) Licensee and Licensor
shall maintain in confidence and shall not disclose to any third-party the Confidential Information received pursuant to this Agreement, without the prior written consent of the other Party except that the Confidential Information may be disclosed
only to those third parties (x) who have a need to know the information in connection with the exercise of rights and obligations under this Agreement and who agree in writing to keep the information confidential to the same extent as is required of
each Party under this Section 10.1, or (y) to whom the Party is legally obligated to disclose the Information. The foregoing obligation shall not apply to: 
  
 (i) information that is known to the other Party or independently developed by the other Party prior to the time of disclosure, in each case, to the extent evidenced by
written records promptly disclosed to the other Party upon receipt of the Confidential Information; or 
  
 (ii) information that becomes patented, published or otherwise part of the public domain as a result of acts by a Party or a third person obtaining such information lawfully as a matter of right; or 
  
 (iii) information that becomes patented, published or otherwise part of the public domain as
a result of acts by the Licensor or a third person obtaining such information lawfully as a matter of right; or 
  
 (iv) information that is required by any law, rule, regulation, order, decision, decree, or subpoena or other judicial, administrative or legal process to be disclosed,
provided, however that each Party, as applicable, gives the other prompt written notice of such request/order to permit the other party to seek a protective order or other similar order with respect to such Confidential Information and thereafter
discloses only the minimum Confidential Information required to be disclosed in order to comply. 
  
 (b) Each Party will take all reasonable steps to protect the Confidential Information of the other Party with the same degree of care it
uses to protect its own confidential proprietary information. Without limiting the foregoing, each party shall ensure that all of its employees having access to the Confidential Information of the other Party are obligated in writing to keep such
information confidential to the same extent as is required of each Party under this Section 10.1. 
  
 10.2 Injunctive Relief. Because damages at law may be an inadequate remedy for breach of any of the covenants, promises and agreements contained in
Section 10.1 hereof, both the Licensor and Licensee shall be entitled to injunctive relief in any state or federal court located within the District of Delaware, including specific performance or an order enjoining the breaching Party from any
threatened or actual breach of such covenants, promises or agreements. Each of the Licensee and the Licensor hereby waives any objection it may have to the personal jurisdiction or venue of any 
  

 11 








 such court with respect to any such action. The rights set forth in this Section 10.2 shall be in addition to any other
rights which the Licensor and Licensee may have at law or in equity. 
  
 10.3 This Article X shall survive the expiration or termination of this Agreement. 
  
 ARTICLE XI 
 TERM AND TERMINATION 
  
 11.1 Term. This Agreement and the licenses granted herein shall commence on the Effective Date and shall continue in effect
in perpetuity subject to earlier termination under Section 11.2 hereof. 
  
 11.2 Termination by the Licensor or Licensee. 
  
 (a) Upon the occurrence of any of the events set forth below (“Events of Default”), the Licensor shall have the right to terminate this Agreement by giving written notice of termination, such termination effective with the giving
of such notice: 
  
 (i) In the event of nonpayment of any material
amount payable to the Licensor after completion of an audit provided for under Section 3.5 hereof, which nonpayment is continuing thirty (30) calendar days after the Licensor gives Licensee written notice of such non-payment. 
  
 (ii) In the event that Licensee fails to initiate clinical trials within two
(2) years of availability of final formulation in quantities adequate for clinical testing and associated documentation for clinical trials, unless such failure is outside of the control of Licensee. See Auxilium Development Plan attached as
Schedule C hereto. 
  
 (iii) In the event that Licensee does not
submit an application for marketing approval in a major market within a five (5) year period after the Effective Date unless such failure to submit is outside of the control of Licensee. 
  
 (iv) In the event that Licensee does not launch Product in a major market within six (6) months after marketing approval.

  
 (v) In the event that Licensee becomes subject to a Bankruptcy
Event provided, however, that so long as Licensor continues to receive royalty payments from Licensee under this Agreement, such Bankruptcy Event shall not be a basis for termination of this Agreement by Licensor. 
  
 (b) Upon the occurrence of any of the events set forth below
(“Events of Default”), Licensee shall have the right to terminate this Agreement by giving written notice of termination, such termination effective with the giving of such notice: 
  
 (i) breach by Licensor of any covenant or any representation or warranty
contained in this Agreement that is continuing thirty (30) calendar days after Licensee gives written notice of such breach; 
  

 12 








 (ii) Licensor fails to comply with the terms of the license granted hereunder and such noncompliance is
continuing thirty (30) calendar days after Licensee gives notice of such noncompliance; 
  
 (iii) Licensor becomes subject to a Bankruptcy Event; or 
  
 (iv) the dissolution or cessation of operations by Licensor. 
  
 (d) No exercise by the Licensor or Licensee of any right of termination shall constitute a waiver of any right of the Licensor or Licensee
for recovery of any monies then due to it hereunder or any other right or remedy the Licensor or Licensee may have at law or under this Agreement. 
  
 ARTICLE XII 
 FORCE MAJEURE 
  
 12.1 Either Party shall be relieved of its obligations under this Agreement
to the extent that fulfillment of such obligations shall be prevented by strikes, embargoes, riots, fires, floods, war, hurricanes, windstorms, acts or defaults of common carriers, governmental laws, acts or regulations, shortages of materials or
any other occurrence, whether or not similar to the foregoing, beyond the reasonable control of the Party affected thereby. 
  
 12.2 If either Party is prevented from fulfilling its obligations under this Agreement by reason of a circumstance covered by this Article 12, the Party
unable to fulfil its obligations shall, upon the occurrence of any such circumstances, promptly notify the other Party upon the cessation of such circumstance and of the likely duration thereof, and shall promptly notify the other party upon the
cessation of such circumstance. 
  
 ARTICLE XIII 
 ADDITIONAL PROVISIONS 
  
 13.1 Arbitration. 
  
 (a) All disputes arising between the Licensor and Licensee under this Agreement shall be settled by arbitration conducted in accordance
with the Rules of the American Arbitration Association. The Parties shall cooperate with each other in causing the arbitration to be held in as efficient and expeditious a manner as practicable. 
  
 (b) Licensee and Licensor each irrevocably and
unconditionally consents to the jurisdiction of any such proceeding and waives any objection that it may have to personal jurisdiction or the laying of venue of any such proceeding. 
  
 13.2 Assignment. No rights hereunder may be assigned by the Licensee, directly or by merger or other operation of law,
except assignment to an Affiliate, without the express written consent of the 
  

 13 








 other Party, such consent not to be unreasonably withheld; provided, however, without such consent, either Party may
assign this Agreement in connection with the sale of all or substantially all of its assets or business or its merger or consolidation with another company. Any prohibited assignment of this Agreement or the rights hereunder shall be null and void.
No assignment shall relieve Licensee or Licensor of responsibility for the performance of any accrued obligations which they have prior to such assignment. This Agreement shall inure to the benefit of permitted assigns. 
  
 13.3 No Waiver. A waiver by either Party of a breach or violation of any
provision of this Agreement will not constitute or be construed as a waiver of any subsequent breach or violation of that provision or as a waiver of any breach or violation of any other provision of this Agreement. 
  
 13.4 Independent Contractor. Nothing herein shall be deemed to establish a
relationship of principal and agent between the Licensor and Licensee, nor any of their agents or employees for any purpose whatsoever. This Agreement shall not be construed as constituting the Licensor and Licensee as partners, or as creating any
other form of legal association or arrangement which could impose liability upon one Party for the act of the other Party. 
  
 13.5 Notices. Any notice under this Agreement shall be sufficiently given if sent in writing by overnight courier, prepaid, first class, certified or
registered mail, return receipt requested, addressed as follows: 
  
 If to the Licensor, to: 
  
 BENTLEY PHARMACEUTICALS, Inc. 
 65 Lafayette Road, 3rd Floor 
 North Hampton, NH 03862-2403 
 Attention: President 
  
 If to the Licensee, to: 
  
 AUXILIUM
A(2), Inc. 
 160 W. Germantown Pike 
 Suite D-5, Norriton Office Center 
 Norristown, PA 19401 
 Attention: President 
 Copy to General Counsel 
  
 or to such other addresses as may be designated from time to time by notice given in accordance with the terms of this Section. 
  
 13.6 Severability. Any of the provisions of this Agreement which are
determined to be invalid or unenforceable in any jurisdiction shall be ineffective to the extent of such invalidity or unenforceability in such jurisdiction, without rendering invalid or unenforceable the remaining provisions hereof or affecting the
validity or unenforceability of any of the terms of this Agreement in any other jurisdiction. 
  

 14 








 13.7 Headings and Titles. Any headings and titles used in this Agreement are for convenience or reference
only and shall not affect its construction or interpretation. 
  
 13.8 No Third Party Benefits. Nothing in this Agreement, express or implied, is intended to confer on any person other than the Parties hereto or their permitted assigns, any benefits, rights or remedies. 
  
 13.9 Governing Law. This Agreement shall be construed, governed, interpreted
and applied in accordance with the laws of the State of Delaware, without giving effect to conflict of law provisions. 
  
 13.10 Counterparts. This Agreement shall become binding when any one or more counterparts hereof, individually or taken together, shall bear the
signatures of each of the parties hereto. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against the party whose signature appears thereon, but all of which taken together shall constitute
but one and the same instrument. 
  
 13.11 Entire Agreement. This
Agreement is the entire agreement between the parties regarding the subject matter herein, and supercedes all prior existing understandings between the Parties relating to the subject matter hereof. This Agreement may not be modified except in
writing signed by both Parties. 
  
 13.12 Press Releases. The
Parties will not disclose, via any press release or public announcement, the existence of this Agreement or the Research Agreement until the Effective Date. 
  
 IN WITNESS WHEREOF, the parties hereto have duly executed this License Agreement as of the date first above written. 
  

									
	 BENTLEY PHARMACEUTICALS, INC.
	 	 	 	 AUXILIUM A2, Inc.

					
	By:	 	/s/    JAMES R. MURPHY        	 	 	 	By:	 	/s/    GERALDINE A. HENWOOD         
	 	 	 James R. Murphy
 Chief Executive Officer
	 	 	 	 	 	 Geraldine A. Henwood
 Chief Executive
Officer


  

 15 








 SCHEDULE A/APPENDIX A 
 BENTLEY PATENTS 
  

							
	 COUNTRY

	 	 PATENT NO.

	 	 GRANT DATE

	 	 EXPIRATION DATE


	 Belgium
	 	248,885	 	Aug. 5, 1992	 	Nov. 28, 2006
	 Canada
	 	1,312,281	 	Jan. 5, 1993	 	Jan. 05, 2010
	 Denmark
	 	167,343	 	Oct. 18, 1993	 	Nov. 28, 2006
	 France
	 	248,885	 	Aug. 5, 1992	 	Nov. 28, 2006
	 Germany
	 	P3,690,626.3	 	May 15, 1997	 	Nov. 28, 2006
	 Great Britain
	 	2,192,134	 	Apr. 25, 1990	 	Nov. 28, 2006
	 Italy
	 	248,885	 	Aug. 5, 1992	 	Nov. 28, 2006
	 Japan
	 	2,583,777	 	Nov. 21, 1996	 	Nov. 28, 2006
	 Korea
	 	84,759	 	Nov. 29, 1994	 	Nov. 28, 2006
	 Luxembourg
	 	WO 873,473	 	Nov. 11, 1987	 	Nov. 28, 2006
	 Switzerland
	 	666,813	 	Aug. 31, 1988	 	Nov. 28, 2006
	 United States
	 	5,023,252	 	June 11, 1991	 	Jun. 11, 2008

  
 Other patents are filed as provisional
applications or are in the preparation or developmental stages and will be amended, if applicable, to this Agreement. 







 SCHEDULE B 
  
 Claims Made Against Bentley Pharmaceuticals, Inc. 
  
 In November 1999, Creative Technologies, Inc. (“Creative”) commenced a lawsuit against the Bentley Pharmaceuticals, Inc. and others in the Superior Court of New
Jersey, Essex County, asserting that the Bentley breached a brokerage or finder’s fee contract with Creative regarding its 1999 acquisition of permeation enhancement technology. Creative also asserts claims for breach of the implied covenant of
good faith and fair dealing and for tortious interference with contract. Bentley has made a motion to dismiss the complaint and each count therein for failure to state a cause of action and for lack of personal jurisdiction over Bentley. 








 AMENDMENT NO. 1 TO LICENSE AGREEMENT 
  
 THIS AMENDMENT NO. 1 TO LICENSE AGREEMENT (the “Amendment”) is made as of the 31st day of October 2000 by
and between BENTLEY PHARMACEUTICALS, INC., a Delaware corporation with offices at 65 Lafayette Road, Third Floor, North Hampton, New Hampshire 03862-2403 (hereinafter “Bentley” or “Licensor”) and AUXILIUM A2 , INC., a Delaware
corporation with offices at 160 W. Germantown Pike, Suite D-5, Norriton Office Center, Norristown, Pennsylvania 19401 (hereafter, “Auxilium” or “Licensee”). Bentley and Auxilium may be referred to as a “Party” or,
collectively, as “Parties.” 
  
 WHEREAS, the parties
have entered into that certain License Agreement dated May 31, 2000 relating to the grant by Bentley to Auxilium of a license of certain technology (the “License Agreement”); 
  
 WHEREAS, as reflected in the third recital of the License Agreement, the parties intended not to include patch applications
as part of the license; 
  
 WHEREAS, the parties wish to clarify
the definitions in the License Agreement to indicate that patch applications are not included in the scope of the license; 
  
 NOW THEREFORE, the parties hereby amend the License Agreement as follows: 
  
 1. The definition of “Combination Products” in Section 1.1 of the License Agreement is hereby modified in its
entirety to read as follows: 
  
 “Combination Products” means any and all pharmaceutical compositions, other than patch applications, which contain (A) testosterone as an active ingredient in combination with any other steroids, hormones, somatotropics,
emollients, or therapeutic soy products; and (B) the Compound; and which fall within the scope of any composition, method, or article claim of the BENTLEY Patents and which is intended to be applied topically to the user of the composition.

  
 2. The definition of “Products” in Section 1.1 of
the License Agreement is hereby modified in its entity to read as follows: 
  
 “Products” means any and all pharmaceutical compositions, other than patch applications, which contain (A) testosterone as the single active ingredient; and (B) the Compound; and which fall within the scope
of any composition, method, or article claim of the BENTLEY Patents and which is intended to be applied topically to the user of the composition. 







 3. As modified by this Amendment, the License Agreement remains in full force and effect. 
  
 IN WITNESS WHEREOF, the parties have executed this Amendment by their duly
authorized representatives as of the date set forth above. 
  

									
	 BENTLEY PHARMACEUTICALS, INC.
	 	 	 	 AUXILIUM A2 , INC.

					
	By:	 	 /s/    JAMES R. MURPHY
	 	 	 	 By:
	 	 /s/    JANE H. HOLLINGSWORTH

	 	 	 Name: James R. Murphy
 Title:   Chairman and CEO
	 	 	 	 	 	 Name: Jane H. Hollingsworth
 Title:   EVP










	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.


  
 AMENDMENT NO. 2 TO LICENSE AGREEMENT

  
 THIS AMENDMENT NO. 2 TO LICENSE AGREEMENT is made as of the
31st day of May, 2001 by and between BENTLEY PHARMACEUTICALS, INC., a Delaware corporation, with offices at 65 Lafayette Road, 3rd Floor, North Hampton, New Hampshire 03862-2403 (hereinafter, “BENTLEY” or “Licensor”), and
AUXILIUM A2, INC., a Delaware corporation having a principal place of business at 160 W. Germantown Pike, Suite D-5, East Norriton, Pennsylvania 19401 (hereinafter, “AUXILIUM” or “Licensee”). BENTLEY and AUXILIUM may be referred
to as a “Party” or, collectively, as “Parties.” 
  
 RECITALS 
  
 WHEREAS the parties have entered into that certain License
Agreement, dated May 31, 2000, relating to the grant by BENTLEY to AUXILIUM of a license of certain technology (the “License Agreement”); 
  
 WHEREAS the parties clarified the License Agreement by entering into Amendment No. 1 to the License Agreement, dated October 31, 2000 (“Amendment No. 1”); and

  
 WHEREAS the Parties wish to further amend the License Agreement to change
certain sections of the License Agreement; 
  
 NOW, THEREFORE, in consideration of
the promises and mutual covenants contained herein, and INTENDING TO BE LEGALLY BOUND HEREBY, the Parties further amend the License Agreement as follows: 
  
 ARTICLE I 
 DEFINITIONS 
  
 1.1 Except as amended below, the terms defined in the License Agreement, as
amended in Amendment No. 1, shall remain unchanged. 
  
 1.2
“Territory” shall mean all countries and territories of the world, including Spain. 
  
 ARTICLE II 
 GRANT OF LICENSE 
  
 2.1 The grant of license in Section 2.1 of the License Agreement shall include Spain. 
  
 ARTICLE III 
 PAYMENTS IN CONSIDERATION FOR LICENSE 
  
 3.1 Except as amended below, all payments set forth in Article III of the License Agreement shall remain unchanged. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.









 3.2 Section 3.2 (a) of the License Agreement shall be amended to read as follows: 
  
 (a) there is an enforceable BENTLEY Patent at the time of
sale: 
  

			
	 The First $[**] Million of Annual Net Sales
	  	[**]%
	 The Next $[**] Million of Annual Net Sales
	  	[**]%
	 The Next $[**] Million of Annual Net Sales
	  	[**]%
	 Net Sales over the First $[**] Million of Annual Net Sales
	  	[**]%

  
 IN WITNESS WHEREOF,
the parties hereto have duly executed this Amendment No. 2 to License Agreement as of the date first above written. 
  

									
	 BENTLEY PHARMACEUTICALS, INC.
	 	 	 	 AUXILIUM A2 , INC.

					
	By:	 	 /s/    JORDAN HORVATH
	 	 	 	 By:
	 	 /s/    GERALDINE A. HENWOOD

	 	 	 Name: Jordan Horvath
 Title:   Vice President & General Counsel
	 	 	 	 	 	 Name: Geraldine A. Henwood
 Title:   Chief Executive Officer


  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.


  

 2 









	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.


  
 AMENDMENT NO. 3 TO LICENSE AGREEMENT 

 
 THIS AMENDMENT NO. 3 TO LICENSE AGREEMENT is made as of the 6th day of
September, 2002 by and between BENTLEY PHARMACEUTICALS, INC., a Delaware corporation, with offices at 65 Lafayette Road, 3rd Floor, North Hampton, New Hampshire 03862-2403 (hereinafter, “BENTLEY” or “Licensor”), and AUXILIUM
PHARMACEUTICALS, INC. (formerly Auxilium A(2), Inc.), a Delaware corporation having a principal place of business at 160 W. Germantown Pike, Suite D-5, East Norriton, Pennsylvania 19401 (hereinafter, “AUXILIUM” or “Licensee”).
BENTLEY and AUXILIUM may be referred to as a “Party” or, collectively, as “Parties.” 
  
 RECITALS 
  
 WHEREAS the parties have entered into that certain License Agreement, dated May 31, 2000, relating to the grant by BENTLEY to AUXILIUM of a license of certain technology (the “License Agreement”); 
  
 WHEREAS the parties clarified certain aspects of the License Agreement by
entering into Amendments Nos. 1 and 2 to the License Agreement, dated October 31, 2000 and May 31, 2001, respectively (“Previous Amendments”); and 
  
 WHEREAS, BENTLEY would like to provide incentives to AUXILIUM to enter into sub-licenses for the Products in territories outside the United States; and

  
 WHEREAS, BENTLEY would like to provide further incentives to
AUXILIUM to extend the commercial life of the Products licensed under the License Agreement; and 
  
 WHEREAS the Parties wish to further amend the License Agreement to change certain sections of the License Agreement; 
  
 NOW, THEREFORE, in consideration of the promises and mutual covenants
contained herein, and INTENDING TO BE LEGALLY BOUND HEREBY, the Parties further amend the License Agreement as follows: 
  
 ARTICLE I 
 DEFINITIONS 
  
 1.1 Except as amended below, the terms defined in the License Agreement, as
amended by the Previous Amendments, shall remain unchanged. Unless otherwise defined in this Amendment, all capitalized terms in this Amendment shall have the meanings ascribed to them in the License Agreement, as amended by the Previous Amendments.

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.









 ARTICLE III 
 PAYMENTS IN CONSIDERATION FOR LICENSE 
  
 3.1 Except as amended below, all payments set forth in Article III of the License Agreement shall remain unchanged. 
  
 3.2 (a) of the License Agreement shall be amended to read as follows: 
  
 (a) there is an enforceable BENTLEY Patent at the time of sale: 
  

			
	All Annual Net Sales in the United States and Canada	  	[**]% beginning at Product launch and continuing for thirty-six full Calendar months thereafter; and [**]% thereafter
		
	All Annual Net Sales outside the United States and Canada	  	[**]% plus [**] of all “Product Royalties” (as defined below) paid to Auxilium which exceed [**]%

  
 “Product
Royalties” shall mean all payments received by Auxilium which are based on sales of Products, but shall not include milestone payments related to achievements which are not sales based. 
  
 ARTICLE IV 
 INTELLECTUAL PROPERTY 
  
 4.1 Article VIII of the License Agreement is amended in its entirety to read as follows: 
  
 8.1 Intellectual Property Rights. The inventorship of inventions developed under this Agreement and relating to Products
(“Inventions”) shall be determined in accordance with U.S. Law. Inventions made solely by employees of BENTLEY or owned by BENTLEY (“BENTLEY Inventions”) shall be the exclusive property of BENTLEY. Inventions made solely by
employees of AUXILIUM (“AUXILIUM Inventions”) shall be the exclusive property of AUXILIUM, except that AUXILIUM Inventions that relate to the use of Products shall be owned by BENTLEY and shall be included in the license granted under this
License Agreement and included in the definition of BENTLEY Patents. Inventions made by employees of BENTLEY and employees of AUXILIUM shall also be owned by BENTLEY and shall be included in the license granted under this License Agreement and
included in the definition of BENTLEY Patents. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.


  
  

 2 








 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment No. 3 to License Agreement as of
the date first above written. 
  

									
	 BENTLEY PHARMACEUTICALS, INC.
	 	 	 	 AUXILIUM PHARMACEUTICALS, INC.

					
	 By:
	 	 /s/    JAMES R. MURPHY
	 	 	 	 By:
	 	 /s/    GERALDINE A. HENWOOD

	 	 	 James R. Murphy
 Chief Executive Officer
	 	 	 	 	 	 Geraldine A. Henwood
 Chief Executive Officer


  
  

 3 








 AMENDMENT NO. 4 TO LICENSE AGREEMENT 
  
 THIS AMENDMENT NO. 4 TO LICENSE AGREEMENT is made as of the 25th day of March, 2004 by and between BENTLEY PHARMACEUTICALS,
INC., a Delaware corporation, with offices at Bentley Park, 2 Holland Way, Exeter, New Hampshire 03833 (hereinafter, “BENTLEY” or “Licensor”), and AUXILIUM PHARMACEUTICALS, INC. (formerly Auxilium A2, Inc.), a Delaware
corporation having a principal place of business at 160 W. Germantown Pike, Norristown, Pennsylvania 19401 (hereinafter, “AUXILIUM” or “Licensee”). BENTLEY and AUXILIUM may be referred to as a “Party” or, collectively,
as “Parties.” 
  
 RECITALS 
  
 WHEREAS the parties have entered into that certain License Agreement, dated May 31, 2000,
relating to the grant by BENTLEY to AUXILIUM of a license of certain technology (the “License Agreement”); 
  
 WHEREAS the parties clarified certain aspects of the License Agreement by entering into Amendment Nos. 1, 2 and 3 to the License Agreement, dated October 31, 2000, May
31, 2001 and September 6, 2002, respectively (“Previous Amendments”); and 
  
 WHEREAS, BENTLEY would like to provide incentives to AUXILIUM to enter into sub-licenses for the Products in territories outside the United States; and 
  

WHEREAS the Parties wish to further amend the License Agreement to clarify certain sections of the License Agreement; 
  
 NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, and
INTENDING TO BE LEGALLY BOUND HEREBY, the Parties further amend the License Agreement as follows: 
  
 ARTICLE I 
 DEFINITIONS 
  
 1.1 Except as amended below, the terms defined in the License Agreement, as amended by the Previous Amendments, shall remain
unchanged. Unless otherwise defined in this Amendment, all capitalized terms in this Amendment shall have the meanings ascribed to them in the License Agreement, as amended by the Previous Amendments. 
  
 “Net Sales Price” means, with respect to the
Product, the gross amount invoiced by Licensee for such Product, less deductions for: 
  
 (i) returned goods; (ii) trade and quantity discounts; (iii) rebates, including those in respect of any governmental subsidized program,
rebate payments given to wholesalers, buying groups, healthcare insurance carriers or other institutions; (iv) sales or other taxes actually paid by Licensee or its sublicensee or distributor, not including 

  

 17 








 
taxes assessed on the income resulting from such sales; and (v) freight allowances, insurance and customs duties, to the extent any of the foregoing are
identified on the invoice for the Product. If Product is sold for consideration other than cash, the fair market value of such other consideration shall be included in Net Sales. If a Product is sold in a package or kit containing another product
which is not a Product, the Net Sales price for purposes of calculating the royalty under Section 3.2 hereof shall be calculated by multiplying the Net Sales Price of the combination product by the fraction of A/A+B, where “A” is the Net
Sales Price of Product when sold separately “B” is the Net Sales Price of the other product or products when sold separately. If either the Product or the other product is not sold separately, the Net Sales Price of the Product shall be
negotiated in good faith by the Parties. 
  
 “Commercial Sale” means the sale of Product (as indicated by shipment of Product) to an unaffiliated third-party of the Licensee, or of its sublicensee or distribution partner, such as a wholesaler, managed care organization,
hospital or pharmacy and shall exclude (i) any transfer of Product by Licensee to its sublicensee, distribution partner or Affiliate and (ii) any distribution of Product for use in research, development, pre-clinical and clinical trials. 

 
 ARTICLE II 
 PAYMENTS IN CONSIDERATION FOR LICENSE 
  
 2.1 Except as amended below, all payments set forth in Article III of the License Agreement shall remain unchanged. 
  
 2.2 Section 3.2 of the License Agreement is hereby amended to include the following additional paragraph (d): 
  
 “(d) Notwithstanding any contrary provisions in this Section 3.2, the royalty payments
due under Sections 3.2 (a), (b) or (c) above shall be paid on a country-by-country basis only until the later of (i) the termination of Bentley Patent rights in such country or (ii) ten years from the date of first Commercial Sale of Product in such
country. 
  

 18 








 ARTICLE III 
 CERTAIN OBLIGATIONS OF LICENSEE 
  
 3.1 A new Section 4.4 shall be added to the License Agreement as follows: 
  
 4.4 Drug Master File. Licensee shall make certain data generated during the research and development of Testim accessible to
Licensor through the preparation and filing of one or more Drug Master Files (“DMF”). Such DMF shall (a) be filed by or on behalf of the Licensee with the United States Food and Drug Administration (“FDA”) on or before June 30,
2004 and (b) shall contain the data listed on the index attached as Exhibit A to this Amendment 4 to the License Agreement (the “Data Index”). Licensee will designate Licensor, or its licensee if requested in writing by Licensor, as having
a right of reference with the FDA to the DMF (the “Right of Reference”). Licensor shall treat the Data Index as confidential information of Licensee and may disclose the Data Index only to those persons or third parties who have agreed in
writing to maintain its confidentiality and to use the Data Index solely for purposes of evaluation of a potential business opportunity with Licensor. 
  
 ARTICLE IV 
 PATENTS, TRADEMARKS AND
INFRINGEMENT 
  
 4.1 Section 9.2(a) of the License Agreement shall
be deleted in its entirety and replaced with the following: 
  
 (a) In the event of Licensor wishing to abandon any BENTLEY Patents, Licensor will offer to assign to Licensee or a sublicense of Licensee, at Licensee’s option, free of charge, any such Patent prior to
effectuating the abandonment. Licensee will bear the costs connected to any assignment hereunder. 
  
 4.2 A new Section 9.6 shall be added to the License Agreement as follows: 
  
 9.6 Bentley Trademark. In cooperation with Licensee, Licensor shall register in the United States
Patent and Trademark Office and such other countries of the world where the trademark is registrable, a trademark to be used to describe the unique qualities of the technology contained in the Bentley Patents (the “New Trademark”).
Licensee shall have a perpetual, royalty free, worldwide, sole and exclusive license with the right to sublicense, to use the New Trademark in connection with the Product or any other product, patents, technology or similar rights licensed from
Licensor now or in the future which contain the ingredient pentadecalactone. Nothing in this Section 9.6 shall prevent Licensee from using or registering any trademark of its own in connection with the Product or any characteristic of or ingredient
in the Product. 
  
 ARTICLE V 
 TERM AND TERMINATION 
  
 5.1 Except as amended below, all provisions of Article XI Term and Termination of the License Agreement shall remain unchanged. 
  

 19 








 5.2 Section 11.1 of the License Agreement shall be deleted in its entirety and replaced with the
following: 
  
 11.1 Term. This Agreement
and the licenses granted herein shall commence on the Effective Date and shall continue until all royalty obligations of Licensee under Section 3.2 of this Agreement are ended, subject to earlier termination under Section 11.2 hereof. Once all such
royalty obligations of Licensee have ended Licensee shall have a fully paid up license under this Agreement. 
  
 5.3 Section 11.2 (a) of the License Agreement shall be deleted in its entirety and replaced with the following: 
  
 (a) Upon the occurrence of any of the events set forth below
(“Events of Default”), the Licensor shall have the right to terminate this Agreement by giving written notice of termination, such termination effective with the giving of such notice: 
  
 (i) In the event of nonpayment of any material amount
payable to the Licensor after completion of an audit provided for under Section 3.5 hereof, which nonpayment is continuing thirty (30) calendar days after the Licensor gives Licensee written notice of such non-payment. 
  
 (ii) In the event that Licensee fails to initiate clinical
trials within two (2) years of availability of final formulation in quantities adequate for clinical testing and associated documentation for clinical trials, unless such failure is outside of the control of Licensee. See Auxilium Development Plan
attached as Schedule C hereto. 
  
 (iii) In the
event that Licensee does not submit an application for marketing approval in a major market within a five (5) year period after the Effective Date unless such failure to submit is outside of the control of Licensee. 
  
 (iv) In the event that Licensee becomes subject to a
Bankruptcy Event provided, however, that so long as Licensor continues to receive royalty payments from Licensee under this Agreement, such Bankruptcy Event shall not be a basis for termination of this Agreement by Licensor. 
  
 ARTICLE VI 
 ADDITIONAL PROVISION 
  
 6.1 Section 13.5 of the License Agreement shall be deleted in its entirety and replaced with the following: 
  
 13.5 Notices. Any notice under this Agreement shall be sufficiently given if sent in writing by overnight courier, prepaid, first
class, certified or registered mail, return receipt requested, addressed as follows: 
  

 20 








 If to the Licensor, to: 
  
 BENTLEY PHARMACEUTICALS, INC. 
 Bentley Park 
 2 Holland Way 
 Exeter, New Hampshire 03833 
 Attention: President 
  
 If to the Licensee, to: 
  
 AUXILIUM
PHARMACEUTICALS, INC. 
 160 W. Germantown Pike 
 Norristown, PA
19401 
 Attention: President 
 Copy to General Counsel

  
 or to such other addresses as may be designated from time to time by notice
given in accordance with the terms of this Section. 
  
 IN WITNESS
WHEREOF, the parties hereto have duly executed this Amendment No. 4 to License Agreement as of the date first above written. 
  

									
	 BENTLEY PHARMACEUTICALS, INC.
	 	 	 	 AUXILIUM PHARMACEUTICALS, INC.

					
	By:	 	  /s/    James R. Murphy
	 	 	 	By:	 	  /s/    Geraldine A Henwood

	 	 	 James R. Murphy
 Chief Executive Officer
	 	 	 	 	 	 Geraldine A. Henwood
 Chief Executive
Officer


  

 21 








 Format and Proposed Contents of the 
 Drug Master File for CPD 
  
 Non-clinical 

	2.6.6	      Toxicology Written Summary 


	2.6.6.1    Summary	


	2.6.6.2    Repeat	Dose Toxicity 


	2.6.6.3    Genotoxicity	


	2.6.6.4    Reproductive	and Developmental Toxicity 

  
 Chemistry 
 3.2.S       Novel Excipient CPD (also known as oxacylcohexadecan-2-one;
CPE-215) 
  
 3.2.S.1    General Information 
 3.2.S.1.1         Nomenclature 
 3.2.S.1.2         Structure 
  
 3.2.S.3    Characterization 
 3.2.S.3.1         Elucidation of Structure and other
Characteristics 
 3.2.S.3.2         Impurities 
  
 3.2.S.4    Control of Novel Excipient 
 3.2.S.4.1         Specification 
 3.2.S.4.2
        Analytical Procedures 
 3.2.S.4.3         Validation of Analytical
Procedures 
  
 3.2.S.5    Reference Standards or Materials

  
 3.2.S.6    Container Closure System 
  
 3.2.S.7    Stability